Kalaris Therapeutics (KLRS)

• Market cap: $93.5M
• 1 day: 6.16%
• 5 days: 3.73%
• 1 month: -37.73%
• 3 months: 96.08%
• 6 months: -7.58%
• Year to date: -51.69%
• 1 year: -78.04%
• 5 years: -99.35%
• 10 years: -99.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.